Page 1

Lantheus FIND FIGHT > FOLLOW ™ Lantheus Holdings , Inc. Reports Second Quarter 2021 Financial Results July 28 , 2021 • Worldwide revenue of $ 101.1 million for the second quarter 2021 , representing an increase of 53.1 % from the prior year period • GAAP net loss of $ 26.7 million for the second quarter 2021 , compared to GAAP net loss of $ 7.0 million in the prior year period • GAAP fully diluted net loss of $ 0.39 for the second quarter 2021 , compared to GAAP fully diluted net loss of $ 0.16 in the prior year period ; adjusted fully diluted EPS of $ 0.11 for the second quarter 2021 , compared to adjusted fully diluted EPS of $ 0.10 in the prior year period • Net cash provided by operating activities was $ 25.9 million for the second quarter 2021. Free cash flow was $ 23.2 million in the second quarter 2021 • The Company provides third quarter 2021 revenue and adjusted diluted earnings per share guidance ; increases full year guidance NORTH BILLERICA , Mass .-- ( BUSINESS WIRE ) -- Jul . 28 , 2021-- Lantheus Holdings , Inc. ( NASDAQ : LNTH ) ( Lantheus ) , an established leader and fully integrated provider of innovative imaging diagnostics , targeted therapeutics and artificial intelligence solutions to find , fight and follow serious medical conditions , today reported financial results for its second quarter ended June 30 , 2021 . The Company's worldwide revenue for the second quarter of 2021 totaled $ 101.1 million , compared with $ 66.0 million for the second quarter of 2020 , representing an increase of 53.1 % from the prior year period . The Company's second quarter 2021 GAAP net loss was $ 26.7 million , or $ 0.39 per fully diluted share , as compared to GAAP net loss of $ 7.0 million , or $ 0.16 per fully diluted share for the second quarter of 2020 . The Company's second quarter 2021 adjusted fully diluted earnings per share were $ 0.11 , as compared to $ 0.10 for the second quarter of 2020 , representing an increase of 8.1 % from the prior year period . Lastly , net cash provided by operating activities was $ 25.9 million for the second quarter 2021. Free Cash Flow was $ 23.2 million in the second quarter of 2021 , representing an increase of approximately $ 27.6 million from the prior year period . " Our second quarter was highlighted by the FDA approval of PYLARIFY , the first and only commercially available PSMA PET imaging agent for prostate cancer , and the strong performance of DEFINITY which exceeded pre COVID - 19 levels , " said Mary Anne Heino , President and Chief Executive Officer . " With the investments Lantheus has made and continues to make in the business , we've laid the foundation to take full advantage of our diversified portfolio of products . We remain committed to delivering on our financial commitments while positively impacting the lives of the patients we serve and delivering shareholder value . " Outlook The Company updates its guidance for full year 2021 and offers the following guidance for the third quarter . Q3 Guidance Issued July 28 , 2021 Previous Guidance Issued May 4 , 2021 Q3 FY 2021 Revenue Q3 FY 2021 Adjusted Diluted EPS $ 95 million - $ 100 million $ 0.05 - $ 0.07 FY Guidance Updated July 28 , 2021 FY 2021 Revenue FY 2021 Adjusted Diluted EPS $ 395 million - $ 402 million $ 0.38 - $ 0.42 N / A N / A FY Guidance Issued May 4 , 2021 $ 390 million - $ 400 million $ 0.36 - $ 0.41 On a forward - looking basis , the Company does not provide GAAP income per common share guidance or a reconciliation of adjusted fully diluted EPS to GAAP income per common share because the Company is unable to predict with reasonable certainty business development and acquisition related expenses , purchase accounting fair value adjustments ( including liability accruals relating to the contingent value rights issued as part of the Progenics Pharmaceuticals , Inc. acquisition ) , and any one - time , non - recurring charges . These items are uncertain , depend on various factors , and could be material to results computed in accordance with GAAP . As a result , it is the Company's view that a quantitative reconciliation of adjusted fully diluted EPS on a forward - looking basis is not available without unreasonable effort . Internet Posting of Information The Company routinely posts information that may be important to investors in the " Investors " section of its website at www.lantheus.com . The Company encourages investors and potential investors to consult its website regularly for important information about the Company . Conference Call and Webcast As previously announced , the Company will host a conference call and webcast on Wednesday , July 28 , 2021 at 8:00 a.m. ET . To access the live conference call via telephone , please dial 1-866-498-8390 ( U.S. callers ) or 1-678-509-7599 ( international callers ) and provide passcode 6149638. A